الفهرس 
ACUTE LEUKEMIAOnly 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
ABSTRACT
Background: Leukemia is one of the most common malignant disorders affecting the world population. Globally In 2020, leukemia was estimated to be 15th and 11th most frequent cause of cancer incidence and cancer-related mortality worldwide 11%, with higher prevalence and overall mortality in the more developed countries. however, the mortality rate, is higher in developing countries.
Aim of the Work: The aim of the present study is to assess the role of Gasdermin D in Adult Acute leukemia Egyptian patients with and without fever.
Patients and Methods: Prospective case control study was conducted on patients diagnosed as Acute leukemia attending clinical hematology unit, internal medicine department, Ain Shams University Hospital, Cairo, Egypt for six months. This study was conducted on patients newly diagnosed with acute leukemia.
Results: There was a significant difference between studied groups regarding Comparison between febrile and afebrile groups regarding laboratory investigations CRP, Procal and Total bilirubin. There was no significant between control and cases groups regarding WBCs, Hb, Platelets, S.Creat, S.albumin, ALT and AST. There was significant difference between studied groups regarding Comparison between Gasdermin D regarding CRP, Procal and PT among the studied patients. There was no significant difference between studied groups regarding Comparison between Gasdermin D regarding Age (yrs) WBCs, Hb, Platelets, S.Creat, S.albumin, ALT, AST, Total bilirubin and Direct bilirubin among the studied patients.
Conclusion: The role of Gasdermin D as a marker of pyroptosis in acute leukemia holds significant promise for advancing our understanding of disease pathogenesis and improving clinical management. Continued research efforts focused on elucidating the complex interplay between pyroptosis pathways and leukemic cell biology are essential for translating these findings into clinically impactful interventions that benefit leukemia patients.